WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 30, 2006--NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the development and sale of proprietary products that help physicians diagnose neuropathies announced today the publication of a study that examined the diagnostic accuracy of the NC-stat System for detection of diabetic polyneuropathy (DPN), which affects over 50% of people with diabetes. DPN has a central role in the development of diabetic foot ulcers, predisposes elderly diabetics to falls and fractures, and is associated with a significant reduction in quality of life. This study provides further support for the clinical utility and diagnostic accuracy of the NC-stat System.
